Kosuke Kato

Dr. Kosuke Kato

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
KKKosuke Kato
Kosuke Kato
IPIoannis Papageorgiou
Ioannis Papageorgiou
YSYoon-Joo Shin
Yoon-Joo Shin
JKJennifer M. Kleinhenz
Jennifer M. Kleinhenz
SPSunny Palumbo
Sunny Palumbo
LHLouise Hecker
Louise Hecker
Idiopathic pulmonary fibrosis (IPF), a severe and deadly form of lung fibrosis, is widely regarded as a disease of aging. We previously demonstrated that aged mice with persistent lung fibrosis and IPF lung myofibroblasts exhibit deficient Nrf2-mediated antioxidant responses. Tecfidera is an orally administered FDA-approved drug for the treatment of multiple sclerosis, where the active pharmaceutical ingredient is dimethyl fumarate (DMF), an active Nrf2 activator. However, no studies have evaluated the efficacy of DMF for age-associated persistent lung fibrosis. Here, we demonstrate that in IPF lung fibroblasts, DMF treatment inhibited both TGF-β-mediated pro-fibrotic phenotypes and led to a reversal of established pro-fibrotic phenotypes. We also evaluated the pre-clinical efficacy of lung-targeted (inhaled) vs. systemic (oral) delivery of DMF in an aging murine model of bleomycin-induced persistent lung fibrosis. DMF or vehicle was administered daily to aged mice by oral gavage or intranasal delivery from 3–6 weeks post-injury when mice exhibited non-resolving lung fibrosis. In contrast to systemic (oral) delivery, only lung-targeted (inhaled) delivery of DMF restored lung Nrf2 expression levels, reduced lung oxidative stress, and promoted the resolution of age-dependent established fibrosis. This is the first study to demonstrate the efficacy of lung-targeted DMF delivery to promote the resolution of age-dependent established lung fibrosis.

16 September 2021 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
KKKosuke Kato
Kosuke Kato
YSYoon-Joo Shin
Yoon-Joo Shin
SPSunny Palumbo
Sunny Palumbo
IPIoannis Papageorgiou
Ioannis Papageorgiou
SHSeongmin Hahn
Seongmin Hahn
LHLouise Hecker
Louise Hecker
Although nintedanib is overwhelmingly prescribed to elderly patients, this is the first study to demonstrate that ageing does not impact the efficacy of nintedanib. This study sheds light on the utility of aged animal models in pulmonary fibrosis.https://bit.ly/3zA9RC5

23 June 2023
Verified
Book Chapter
Closed access
PDF file
LHLouise Hecker
Louise Hecker
KKKosuke Kato
Kosuke Kato
KGKathy K. Griendling
Kathy K. Griendling


1 May 2023
Verified
Conference Paper
Closed access
KKKosuke Kato
Kosuke Kato
IPI. Papageorgiou
I. Papageorgiou
YSYoon Joo Shin
Yoon Joo Shin
JKJ. Kleinhenz
J. Kleinhenz
LHL. Hecker
L. Hecker

1 May 2023
Verified
Conference Paper
Closed access
LHL. Hecker
L. Hecker
KKKosuke Kato
Kosuke Kato
JPJ. Papageorgiou
J. Papageorgiou
VGV. Gokhale
V. Gokhale